Work

Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.6029

Authors: Alain Patrick Algazi, Dhaval Shah, William Smith, Timothy J. Panella, Dong Moon Shin, Justine Yang Bruce, Ramzi Melhem, Jean S. Campbell, Lauren Abell, Marie-Louise Fjaellskog, John K. Celebi, Robert Hamilton Pierce, Ann Wild Gramza

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Medical Oncology Hematology Consultants, University of Tennessee Medical Center, Winship Cancer Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Sensei Biotherapeutics (United States), OncoSec Medical (United States), Fred Hutch Cancer Center, National Institutes of Health, National Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3172858633

Cites:

Cited by: 1

Related to: 10